{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:57Z","timestamp":1791676137536,"version":"4.3.4"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation ARC"},{"name":"ANR","award":["ANR-23-CE17-0016"],"award-info":[{"award-number":["ANR-23-CE17-0016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The infiltration of tumors by CD8\u207a T lymphocytes is a critical determinant of antitumor immunity and response to immunotherapy. However, the presence of tumor-specific CD8\u207a T cells does not necessarily translate into effective tumor control, as multiple biological barriers can prevent their recruitment, spatial distribution, persistence, and functional activity. This review provides a comprehensive overview of the multistep mechanisms regulating CD8\u207a T-cell infiltration, from immune priming and systemic trafficking to vascular entry, intratumoral migration, and tissue residency. We discuss how alterations in chemokine networks, dysfunctional tumor vasculature, extracellular matrix remodeling, stromal barriers, and immunosuppressive signals collectively drive immune exclusion and resistance to therapy. Unlike previous reviews that have focused on individual aspects of T-cell trafficking, tumor immune contexture, or immune exclusion, we integrate these interconnected mechanisms as successive biological checkpoints and link them to therapeutic strategies aimed at overcoming specific barriers. These include restoration of antigen presentation and dendritic cell function, reprogramming of chemokine pathways, vascular normalization, stromal remodeling, innate immune activation, and induction of tertiary lymphoid structures. This integrated framework highlights why increasing CD8\u207a T-cell infiltration alone may be insufficient and supports the development of rational, sequential, and spatially guided combination strategies. Advances in spatial transcriptomics, single-cell technologies, and multiplex imaging are expected to enable personalized identification of dominant immune barriers and rational design of combination therapies. Ultimately, the goal is shifting from simply activating T cells toward engineering tumor ecosystems that support sustained CD8\u207a T-cell infiltration, organization, and effector function.<\/jats:p>","DOI":"10.1186\/s43556-026-00612-3","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:16:04Z","timestamp":1791627364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD8\u207a T Cell infiltration and spatial organization in cancer: mechanisms, barriers, and therapeutic strategies"],"prefix":"10.1186","volume":"7","author":[{"given":"Lylou","family":"Milian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-1998","authenticated-orcid":false,"given":"Mannon","family":"Geindreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandre","family":"Pignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-1441","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Vegran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"issue":"1","key":"612_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/cam4.1889","volume":"8","author":"S Shimizu","year":"2019","unstructured":"Shimizu S, Hiratsuka H, Koike K, Tsuchihashi K, Sonoda T, Ogi K, et al. Tumor-infiltrating CD8(+) T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8(1):80\u201393. https:\/\/doi.org\/10.1002\/cam4.1889.","journal-title":"Cancer Med"},{"issue":"5795","key":"612_CR2","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134. https:\/\/doi.org\/10.1126\/science.1129139.","journal-title":"Science"},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59. https:\/\/doi.org\/10.1186\/s40425-016-0165-6.","journal-title":"J Immunother Cancer"},{"issue":"33","key":"612_CR4","doi-asserted-by":"publisher","first-page":"52849","DOI":"10.18632\/oncotarget.10811","volume":"7","author":"M Uso","year":"2016","unstructured":"Uso M, Jantus-Lewintre E, Bremnes RM, Calabuig S, Blasco A, Pastor E, et al. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. Oncotarget. 2016;7(33):52849\u201361. https:\/\/doi.org\/10.18632\/oncotarget.10811.","journal-title":"Oncotarget"},{"issue":"4","key":"612_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2326-6066.CIR-17-0360","volume":"6","author":"RD Gartrell","year":"2018","unstructured":"Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, et al. Quantitative analysis of immune infiltrates in primary melanoma. Cancer Immunol Res. 2018;6(4):481\u201393. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0360.","journal-title":"Cancer Immunol Res"},{"key":"612_CR6","doi-asserted-by":"publisher","unstructured":"Casalegno Garduno R, Spitschak A, Pannek T, Putzer BM. CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy. Biomedicines. 2025;13(4). https:\/\/doi.org\/10.3390\/biomedicines13040930","DOI":"10.3390\/biomedicines13040930"},{"issue":"1","key":"612_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"612_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.tcb.2025.05.006","volume":"36","author":"G Grant","year":"2026","unstructured":"Grant G, Ferrer CM. The role of the immune tumor microenvironment in shaping metastatic dissemination, dormancy, and outgrowth. Trends Cell Biol. 2026;36(5):377\u201391. https:\/\/doi.org\/10.1016\/j.tcb.2025.05.006.","journal-title":"Trends Cell Biol"},{"issue":"27","key":"612_CR9","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","volume":"26","author":"MC Dieu-Nosjean","year":"2008","unstructured":"Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.15.0284.","journal-title":"J Clin Oncol"},{"issue":"8","key":"612_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.trecan.2022.04.003","volume":"8","author":"KA Tooley","year":"2022","unstructured":"Tooley KA, Escobar G, Anderson AC. Spatial determinants of CD8(+) T cell differentiation in cancer. Trends Cancer. 2022;8(8):642\u201354. https:\/\/doi.org\/10.1016\/j.trecan.2022.04.003.","journal-title":"Trends Cancer"},{"issue":"3","key":"612_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74(3):705\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1342.","journal-title":"Cancer Res"},{"issue":"1","key":"612_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z, et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct Target Ther. 2024;9(1):225. https:\/\/doi.org\/10.1038\/s41392-024-01947-5.","journal-title":"Signal Transduct Target Ther"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2016.00407","volume":"7","author":"C Sautes-Fridman","year":"2016","unstructured":"Sautes-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, et al. Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Front Immunol. 2016;7:407. https:\/\/doi.org\/10.3389\/fimmu.2016.00407.","journal-title":"Front Immunol"},{"issue":"8","key":"612_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00262-025-04108-x","volume":"74","author":"NN Dai","year":"2025","unstructured":"Dai NN, Hu MY, Wang JP, Dai ZH, Xu L, Ye TW. Tertiary lymphoid structures in the microenvironment of colorectal cancer: exploring new therapeutic targets. Cancer Immunol Immunother. 2025;74(8):245. https:\/\/doi.org\/10.1007\/s00262-025-04108-x.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"612_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41419-025-08180-0","volume":"16","author":"Z Xie","year":"2025","unstructured":"Xie Z, Fang Y, Zhang X, Fang Y, Li R, Guo Y, et al. The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy. Cell Death Dis. 2025;16(1):900. https:\/\/doi.org\/10.1038\/s41419-025-08180-0.","journal-title":"Cell Death Dis"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"1562248","DOI":"10.3389\/fimmu.2025.1562248","volume":"16","author":"Z Qin","year":"2025","unstructured":"Qin Z, Xu T. Deciphering the deterministic role of TCR signaling in T cell fate determination. Front Immunol. 2025;16:1562248. https:\/\/doi.org\/10.3389\/fimmu.2025.1562248.","journal-title":"Front Immunol"},{"key":"612_CR17","doi-asserted-by":"publisher","unstructured":"Sun X, Liu W, Sun L, Mo H, Feng Y, Wu X, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10(11). https:\/\/doi.org\/10.1136\/jitc-2022-005531.","DOI":"10.1136\/jitc-2022-005531"},{"issue":"11","key":"612_CR18","first-page":"14725","volume":"8","author":"K Li","year":"2015","unstructured":"Li K, Zhu Z, Luo J, Fang J, Zhou H, Hu M, et al. Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer. Int J Clin Exp Pathol. 2015;8(11):14725\u201332.","journal-title":"Int J Clin Exp Pathol"},{"issue":"21","key":"612_CR19","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1158\/0008-5472.CAN-04-2059","volume":"64","author":"IM Mullins","year":"2004","unstructured":"Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 2004;64(21):7697\u2013701. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2059.","journal-title":"Cancer Res"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.007.","journal-title":"Cancer Treat Rev"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","volume":"8","author":"M Metzemaekers","year":"2017","unstructured":"Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P. Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands. Front Immunol. 2017;8:1970. https:\/\/doi.org\/10.3389\/fimmu.2017.01970.","journal-title":"Front Immunol"},{"issue":"2","key":"612_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26(2):487\u2013504. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1868.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"612_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1158\/2326-6066.CIR-20-0499","volume":"9","author":"IL Gomes-Santos","year":"2021","unstructured":"Gomes-Santos IL, Amoozgar Z, Kumar AS, Ho WW, Roh K, Talele NP, et al. Exercise training improves tumor control by increasing CD8(+) T-cell infiltration via CXCR3 signaling and sensitizes breast cancer to immune checkpoint blockade. Cancer Immunol Res. 2021;9(7):765\u201378. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0499.","journal-title":"Cancer Immunol Res"},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"107327482412411","DOI":"10.1177\/10732748241241162","volume":"31","author":"J Wang","year":"2024","unstructured":"Wang J, Ouyang X, Zhu W, Yi Q, Zhong J. The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets. Cancer Control. 2024;31:10732748241241162. https:\/\/doi.org\/10.1177\/10732748241241162.","journal-title":"Cancer Control"},{"issue":"1","key":"612_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12885-018-4384-8","volume":"18","author":"C Zhang","year":"2018","unstructured":"Zhang C, Li Z, Xu L, Che X, Wen T, Fan Y, et al. CXCL9\/10\/11, a regulator of PD-L1 expression in gastric cancer. BMC Cancer. 2018;18(1):462. https:\/\/doi.org\/10.1186\/s12885-018-4384-8.","journal-title":"BMC Cancer"},{"issue":"16","key":"612_CR26","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1158\/0008-5472.CAN-11-1687","volume":"71","author":"A Gonzalez-Martin","year":"2011","unstructured":"Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. 2011;71(16):5455\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1687.","journal-title":"Cancer Res"},{"key":"612_CR27","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3389\/fimmu.2019.02395","volume":"10","author":"PY Chen","year":"2019","unstructured":"Chen PY, Wu CY, Fang JH, Chen HC, Feng LY, Huang CY, et al. Functional Change of Effector Tumor-Infiltrating CCR5(+)CD38(+)HLA-DR(+)CD8(+) T Cells in Glioma Microenvironment. Front Immunol. 2019;10:2395. https:\/\/doi.org\/10.3389\/fimmu.2019.02395.","journal-title":"Front Immunol"},{"issue":"6","key":"612_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/ijc.21135","volume":"116","author":"H Musha","year":"2005","unstructured":"Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer. 2005;116(6):949\u201356. https:\/\/doi.org\/10.1002\/ijc.21135.","journal-title":"Int J Cancer"},{"issue":"2","key":"612_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1023\/a:1011059906777","volume":"21","author":"YF Yang","year":"2001","unstructured":"Yang YF, Tomura M, Iwasaki M, Mukai T, Gao P, Ono S, et al. IL-12 as well as IL-2 upregulates CCR5 expression on T cell receptor-triggered human CD4+ and CD8+ T cells. J Clin Immunol. 2001;21(2):116\u201325. https:\/\/doi.org\/10.1023\/a:1011059906777.","journal-title":"J Clin Immunol"},{"issue":"6","key":"612_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1023\/a:1013173610032","volume":"21","author":"YF Yang","year":"2001","unstructured":"Yang YF, Tomura M, Iwasaki M, Ono S, Zou JP, Uno K, et al. IFN-alpha acts on T-cell receptor-triggered human peripheral leukocytes to up-regulate CCR5 expression on CD4+ and CD8+ T cells. J Clin Immunol. 2001;21(6):402\u20139. https:\/\/doi.org\/10.1023\/a:1013173610032.","journal-title":"J Clin Immunol"},{"issue":"9","key":"612_CR31","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.4049\/jimmunol.1501176","volume":"196","author":"D Askew","year":"2016","unstructured":"Askew D, Su CA, Barkauskas DS, Dorand RD, Myers J, Liou R, et al. Transient surface CCR5 expression by naive CD8+ T cells within inflamed lymph nodes is dependent on high endothelial venule interaction and augments Th cell-dependent memory response. J Immunol. 2016;196(9):3653\u201364. https:\/\/doi.org\/10.4049\/jimmunol.1501176.","journal-title":"J Immunol"},{"issue":"21","key":"612_CR32","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.1073\/pnas.1100567108","volume":"108","author":"Y Kumamoto","year":"2011","unstructured":"Kumamoto Y, Mattei LM, Sellers S, Payne GW, Iwasaki A. CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc Natl Acad Sci U S A. 2011;108(21):8749\u201354. https:\/\/doi.org\/10.1073\/pnas.1100567108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2-3","key":"612_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.imlet.2003.12.009","volume":"91","author":"PF Vitiello","year":"2004","unstructured":"Vitiello PF, Shainheit MG, Allison EM, Adler EP, Kurt RA. Impact of tumor-derived CCL2 on T cell effector function. Immunol Lett. 2004;91(2\u20133):239\u201345. https:\/\/doi.org\/10.1016\/j.imlet.2003.12.009.","journal-title":"Immunol Lett"},{"issue":"3","key":"612_CR34","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1172\/JCI80071","volume":"126","author":"N Jacquelot","year":"2016","unstructured":"Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, et al. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest. 2016;126(3):921\u201337. https:\/\/doi.org\/10.1172\/JCI80071.","journal-title":"J Clin Invest"},{"issue":"3","key":"612_CR35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2767-9764.CRC-22-0383","volume":"3","author":"E Abdelfatah","year":"2023","unstructured":"Abdelfatah E, Long MD, Kajihara R, Oba T, Yamauchi T, Chen H, et al. Predictive and Prognostic Implications of Circulating CX3CR1(+) CD8(+) T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. Cancer Res Commun. 2023;3(3):510\u201320. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0383.","journal-title":"Cancer Res Commun"},{"key":"612_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9306","volume":"6","author":"JP Bottcher","year":"2015","unstructured":"Bottcher JP, Beyer M, Meissner F, Abdullah Z, Sander J, Hochst B, et al. Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat Commun. 2015;6:8306. https:\/\/doi.org\/10.1038\/ncomms9306.","journal-title":"Nat Commun"},{"key":"612_CR37","doi-asserted-by":"publisher","unstructured":"Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018;3(8). https:\/\/doi.org\/10.1172\/jci.insight.97828","DOI":"10.1172\/jci.insight.97828"},{"issue":"7","key":"612_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021546","volume":"6","author":"F Gaudin","year":"2011","unstructured":"Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadiere C, Prevot S, et al. Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS ONE. 2011;6(7):e21546. https:\/\/doi.org\/10.1371\/journal.pone.0021546.","journal-title":"PLoS ONE"},{"issue":"6","key":"612_CR39","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.immuni.2016.10.018","volume":"45","author":"C Gerlach","year":"2016","unstructured":"Gerlach C, Moseman EA, Loughhead SM, Alvarez D, Zwijnenburg AJ, Waanders L, et al. The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis. Immunity. 2016;45(6):1270\u201384. https:\/\/doi.org\/10.1016\/j.immuni.2016.10.018.","journal-title":"Immunity"},{"key":"612_CR40","doi-asserted-by":"publisher","unstructured":"Yamauchi T, Hoki T, Oba T, Saito H, Attwood K, Sabel MS, et al. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. JCI Insight. 2020;5(8). https:\/\/doi.org\/10.1172\/jci.insight.133920.","DOI":"10.1172\/jci.insight.133920"},{"issue":"12","key":"612_CR41","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1084\/jem.20181308","volume":"216","author":"AN Wein","year":"2019","unstructured":"Wein AN, McMaster SR, Takamura S, Dunbar PR, Cartwright EK, Hayward SL, et al. CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways. J Exp Med. 2019;216(12):2748\u201362. https:\/\/doi.org\/10.1084\/jem.20181308.","journal-title":"J Exp Med"},{"key":"612_CR42","doi-asserted-by":"publisher","unstructured":"Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, et al. CXCR6 by increasing retention of memory CD8(+) T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021;9(10). https:\/\/doi.org\/10.1136\/jitc-2021-003329.","DOI":"10.1136\/jitc-2021-003329"},{"key":"612_CR43","doi-asserted-by":"publisher","unstructured":"Wang B, Wang Y, Sun X, Deng G, Huang W, Wu X, et al. CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell. J Immunother Cancer. 2021;9(8). https:\/\/doi.org\/10.1136\/jitc-2021-003100","DOI":"10.1136\/jitc-2021-003100"},{"issue":"2","key":"612_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0092-8674(94)90337-9","volume":"76","author":"TA Springer","year":"1994","unstructured":"Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76(2):301\u201314. https:\/\/doi.org\/10.1016\/0092-8674(94)90337-9.","journal-title":"Cell"},{"issue":"9","key":"612_CR45","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678\u201389. https:\/\/doi.org\/10.1038\/nri2156.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"612_CR46","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2217\/imt.11.100","volume":"3","author":"JC Nolz","year":"2011","unstructured":"Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy. 2011;3(10):1223\u201333. https:\/\/doi.org\/10.2217\/imt.11.100.","journal-title":"Immunotherapy"},{"issue":"7193","key":"612_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nature06868","volume":"453","author":"J Hamzah","year":"2008","unstructured":"Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(7193):410\u20134. https:\/\/doi.org\/10.1038\/nature06868.","journal-title":"Nature"},{"issue":"12","key":"612_CR48","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"HR Park","year":"2023","unstructured":"Park HR, Shiva A, Cummings P, Kim S, Kim S, Lee E, et al. Angiopoietin-2-Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma. Cancer Res. 2023;83(12):1968\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2838.","journal-title":"Cancer Res"},{"issue":"1","key":"612_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","volume":"14","author":"RJ Buckanovich","year":"2008","unstructured":"Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14(1):28\u201336. https:\/\/doi.org\/10.1038\/nm1699.","journal-title":"Nat Med"},{"issue":"6","key":"612_CR50","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607\u201315. https:\/\/doi.org\/10.1038\/nm.3541.","journal-title":"Nat Med"},{"issue":"5","key":"612_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29.","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"612_CR52","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","volume":"70","author":"RK Shrimali","year":"2010","unstructured":"Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0153.","journal-title":"Cancer Res"},{"issue":"5","key":"612_CR53","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.immuni.2014.10.008","volume":"41","author":"S Nourshargh","year":"2014","unstructured":"Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity. 2014;41(5):694\u2013707. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.008.","journal-title":"Immunity"},{"key":"612_CR54","doi-asserted-by":"publisher","first-page":"1340702","DOI":"10.3389\/fimmu.2024.1340702","volume":"15","author":"D Lv","year":"2024","unstructured":"Lv D, Fei Y, Chen H, Wang J, Han W, Cui B, et al. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment. Front Immunol. 2024;15:1340702. https:\/\/doi.org\/10.3389\/fimmu.2024.1340702.","journal-title":"Front Immunol"},{"key":"612_CR55","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2019","unstructured":"Henke E, Nandigama R, Ergun S. Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Front Mol Biosci. 2019;6:160. https:\/\/doi.org\/10.3389\/fmolb.2019.00160.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"612_CR56","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41590-024-01792-2","volume":"25","author":"JH Chen","year":"2024","unstructured":"Chen JH, Nieman LT, Spurrell M, Jorgji V, Elmelech L, Richieri P, et al. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat Immunol. 2024;25(4):644\u201358. https:\/\/doi.org\/10.1038\/s41590-024-01792-2.","journal-title":"Nat Immunol"},{"issue":"5","key":"612_CR57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ccell.2023.03.015","volume":"41","author":"G Gaglia","year":"2023","unstructured":"Gaglia G, Burger ML, Ritch CC, Rammos D, Dai Y, Crossland GE, et al. Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. Cancer Cell. 2023;41(5):871-86 e10. https:\/\/doi.org\/10.1016\/j.ccell.2023.03.015.","journal-title":"Cancer Cell"},{"key":"612_CR58","doi-asserted-by":"publisher","unstructured":"Hoch T, Schulz D, Eling N, Gomez JM, Levesque MP, Bodenmiller B. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci Immunol. 2022;7(70):eabk1692. https:\/\/doi.org\/10.1126\/sciimmunol.abk1692","DOI":"10.1126\/sciimmunol.abk1692"},{"issue":"12","key":"612_CR59","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.devcel.2023.04.010","volume":"58","author":"LF Tshering","year":"2023","unstructured":"Tshering LF, Luo F, Russ S, Szenk M, Rubel D, Tutuska K, et al. Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Dev Cell. 2023;58(12):1071-86 e8. https:\/\/doi.org\/10.1016\/j.devcel.2023.04.010.","journal-title":"Dev Cell"},{"issue":"6","key":"612_CR60","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen A, Hamon P, Fiaschi N, Soong BY, Park MD, Mattiuz R, et al. Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023;29(6):1389\u201399. https:\/\/doi.org\/10.1038\/s41591-023-02345-0.","journal-title":"Nat Med"},{"issue":"6","key":"612_CR61","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow MT, Ozga AJ, Servis RL, Frederick DT, Lo JA, Fisher DE, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity. 2019;50(6):1498-1512 e5. https:\/\/doi.org\/10.1016\/j.immuni.2019.04.010.","journal-title":"Immunity"},{"key":"612_CR62","doi-asserted-by":"publisher","unstructured":"Vahidian F, Lamaze FC, Bouffard C, Coulombe F, Gagne A, Blais F, et al. CXCL13 positive cells localization predict response to anti-PD-1\/PD-L1 in pulmonary non-small cell carcinoma. Cancers (Basel). 2024;16(4). https:\/\/doi.org\/10.3390\/cancers16040708.","DOI":"10.3390\/cancers16040708"},{"issue":"8","key":"612_CR63","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s12094-025-03874-5","volume":"27","author":"LB Kwantwi","year":"2025","unstructured":"Kwantwi LB, Boafo JD, Egleh BE, Li M. CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches. Clin Transl Oncol. 2025;27(8):3285\u201392. https:\/\/doi.org\/10.1007\/s12094-025-03874-5.","journal-title":"Clin Transl Oncol"},{"key":"612_CR64","doi-asserted-by":"publisher","unstructured":"Xu L, Ye L, Huang Q. Tissue-Resident Memory CD8+ T Cells: Differentiation, Phenotypic Heterogeneity, Biological Function, Disease, and Therapy. MedComm (2020). 2025;6(3):e70132. https:\/\/doi.org\/10.1002\/mco2.70132","DOI":"10.1002\/mco2.70132"},{"issue":"6","key":"612_CR65","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.immuni.2015.11.008","volume":"43","author":"LK Mackay","year":"2015","unstructured":"Mackay LK, Wynne-Jones E, Freestone D, Pellicci DG, Mielke LA, Newman DM, et al. T-box Transcription Factors Combine with the Cytokines TGF-beta and IL-15 to Control Tissue-Resident Memory T Cell Fate. Immunity. 2015;43(6):1101\u201311. https:\/\/doi.org\/10.1016\/j.immuni.2015.11.008.","journal-title":"Immunity"},{"issue":"7083","key":"612_CR66","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nature04606","volume":"440","author":"LR Shiow","year":"2006","unstructured":"Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, et al. CD69 acts downstream of interferon-alpha\/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 2006;440(7083):540\u20134. https:\/\/doi.org\/10.1038\/nature04606.","journal-title":"Nature"},{"issue":"5","key":"612_CR67","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.4049\/jimmunol.1402256","volume":"194","author":"LK Mackay","year":"2015","unstructured":"Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedoui S, et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol. 2015;194(5):2059\u201363. https:\/\/doi.org\/10.4049\/jimmunol.1402256.","journal-title":"J Immunol"},{"key":"612_CR68","doi-asserted-by":"publisher","unstructured":"Okla K, Farber DL, Zou W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med. 2021;218(4). https:\/\/doi.org\/10.1084\/jem.20201605","DOI":"10.1084\/jem.20201605"},{"key":"612_CR69","doi-asserted-by":"publisher","unstructured":"Heim TA, Ibrahim O, Lin Z, Schultz AC, Steele MM, Mudianto T, et al. CXCR6 promotes dermal CD8+ T cell survival and transition to long-term tissue residence. J Immunol. 2026;215(1). https:\/\/doi.org\/10.1093\/jimmun\/vkaf219","DOI":"10.1093\/jimmun\/vkaf219"},{"issue":"10","key":"612_CR70","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1158\/0008-5472.CAN-06-3424","volume":"67","author":"S Hojo","year":"2007","unstructured":"Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 2007;67(10):4725\u201331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3424.","journal-title":"Cancer Res"},{"key":"612_CR71","doi-asserted-by":"publisher","unstructured":"Di Pilato M, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184(17):4512\u201330 e22. https:\/\/doi.org\/10.1016\/j.cell.2021.07.015","DOI":"10.1016\/j.cell.2021.07.015"},{"key":"612_CR72","doi-asserted-by":"publisher","unstructured":"Jenkins E, Whitehead T, Fellermeyer M, Davis SJ, Sharma S. The current state and future of T-cell exhaustion research. Oxf Open Immunol. 2023;4(1):iqad006. https:\/\/doi.org\/10.1093\/oxfimm\/iqad006","DOI":"10.1093\/oxfimm\/iqad006"},{"issue":"8","key":"612_CR73","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1007\/s00432-022-04440-0","volume":"149","author":"M Davern","year":"2023","unstructured":"Davern M, Donlon NE, O\u2019Connell F, Gaughan C, O\u2019Donovan C, McGrath J, et al. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy. J Cancer Res Clin Oncol. 2023;149(8):5377\u201395. https:\/\/doi.org\/10.1007\/s00432-022-04440-0.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"612_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101479","volume":"5","author":"RJ Lim","year":"2024","unstructured":"Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, et al. CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Rep Med. 2024;5(4):101479. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101479.","journal-title":"Cell Rep Med"},{"key":"612_CR75","doi-asserted-by":"publisher","unstructured":"Yilmaz A, Haerri L, Granda ME, Coquoz O, Lan Q, Ruegg C. The CXCL10\/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer. NPJ Breast Cancer. 2026;12(1). https:\/\/doi.org\/10.1038\/s41523-026-00903-6","DOI":"10.1038\/s41523-026-00903-6"},{"key":"612_CR76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2021.03.002","volume":"506","author":"Y Yan","year":"2021","unstructured":"Yan Y, Zheng L, Du Q, Yazdani H, Dong K, Guo Y, et al. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10\/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 2021;506:95\u2013106. https:\/\/doi.org\/10.1016\/j.canlet.2021.03.002.","journal-title":"Cancer Lett"},{"key":"612_CR77","doi-asserted-by":"publisher","unstructured":"Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y, et al. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J Immunother Cancer. 2022;10(5). https:\/\/doi.org\/10.1136\/jitc-2021-003960","DOI":"10.1136\/jitc-2021-003960"},{"issue":"2","key":"612_CR78","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/bjc.2015.193","volume":"113","author":"SC Wightman","year":"2015","unstructured":"Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, et al. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer. 2015;113(2):327\u201335. https:\/\/doi.org\/10.1038\/bjc.2015.193.","journal-title":"Br J Cancer"},{"issue":"7559","key":"612_CR79","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135. https:\/\/doi.org\/10.1038\/nature14404.","journal-title":"Nature"},{"key":"612_CR80","doi-asserted-by":"publisher","unstructured":"Chen J, Ge Q, He J, Bian Z, Yu H, Li C, et al. Mutant p53 epigenetically rewires CXCL10 to promote CD8(+) T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer. J Exp Clin Cancer Res. 2026;45(1). https:\/\/doi.org\/10.1186\/s13046-026-03672-z","DOI":"10.1186\/s13046-026-03672-z"},{"issue":"7577","key":"612_CR81","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249\u201353. https:\/\/doi.org\/10.1038\/nature15520.","journal-title":"Nature"},{"key":"612_CR82","doi-asserted-by":"publisher","unstructured":"Korbecki J, Kojder K, Barczak K, Siminska D, Gutowska I, Chlubek D, et al. Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor-A Literature Review. Int J Mol Sci. 2020;21(16). https:\/\/doi.org\/10.3390\/ijms21165647","DOI":"10.3390\/ijms21165647"},{"issue":"1","key":"612_CR83","doi-asserted-by":"publisher","first-page":"2144669","DOI":"10.1080\/2162402X.2022.2144669","volume":"11","author":"A Vienot","year":"2022","unstructured":"Vienot A, Pallandre JR, Renaude E, Viot J, Bouard A, Spehner L, et al. Chemokine switch regulated by TGF-beta1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy. Oncoimmunology. 2022;11(1):2144669. https:\/\/doi.org\/10.1080\/2162402X.2022.2144669.","journal-title":"Oncoimmunology"},{"issue":"4","key":"612_CR84","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012;22(4):275\u201381. https:\/\/doi.org\/10.1016\/j.semcancer.2012.01.011.","journal-title":"Semin Cancer Biol"},{"issue":"7355","key":"612_CR85","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u20135. https:\/\/doi.org\/10.1038\/nature10138.","journal-title":"Nature"},{"issue":"2","key":"612_CR86","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/eji.200526208","volume":"36","author":"T Zhang","year":"2006","unstructured":"Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol. 2006;36(2):457\u201367. https:\/\/doi.org\/10.1002\/eji.200526208.","journal-title":"Eur J Immunol"},{"issue":"50","key":"612_CR87","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212\u20137. https:\/\/doi.org\/10.1073\/pnas.1320318110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"612_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13402-026-01165-x","volume":"49","author":"J Wang","year":"2026","unstructured":"Wang J, Zhou Y, Han X, Zhao Y, Chen A, Chen Y, et al. CXCL12 derived from cancer-associated fibroblasts mediates dysfunctional intratumoral adaptive immunity in diabetic pancreatic adenocarcinoma. Cell Oncol (Dordr). 2026;49(1):36. https:\/\/doi.org\/10.1007\/s13402-026-01165-x.","journal-title":"Cell Oncol (Dordr)"},{"key":"612_CR89","doi-asserted-by":"publisher","unstructured":"Song D, Wu Y, Li J, Liu J, Yi Z, Wang X, et al. Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy. J Clin Invest. 2024;134(22). https:\/\/doi.org\/10.1172\/JCI183366.","DOI":"10.1172\/JCI183366"},{"issue":"10","key":"612_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077537","volume":"8","author":"GC Preston","year":"2013","unstructured":"Preston GC, Feijoo-Carnero C, Schurch N, Cowling VH, Cantrell DA. The impact of KLF2 modulation on the transcriptional program and function of CD8 T cells. PLoS ONE. 2013;8(10):e77537. https:\/\/doi.org\/10.1371\/journal.pone.0077537.","journal-title":"PLoS ONE"},{"issue":"3","key":"612_CR91","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1046\/j.1365-2443.2002.00515.x","volume":"7","author":"K Ogasawara","year":"2002","unstructured":"Ogasawara K, Hida S, Weng Y, Saiura A, Sato K, Takayanagi H, et al. Requirement of the IFN-alpha\/beta-induced CXCR3 chemokine signalling for CD8+ T cell activation. Genes Cells. 2002;7(3):309\u201320. https:\/\/doi.org\/10.1046\/j.1365-2443.2002.00515.x.","journal-title":"Genes Cells"},{"issue":"6","key":"612_CR92","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0","volume":"32","author":"C Nakajima","year":"2002","unstructured":"Nakajima C, Mukai T, Yamaguchi N, Morimoto Y, Park WR, Iwasaki M, et al. Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation. Eur J Immunol. 2002;32(6):1792\u2013801. https:\/\/doi.org\/10.1002\/1521-4141(200206)32:6%3c1792::AID-IMMU1792%3e3.0.CO;2-0.","journal-title":"Eur J Immunol"},{"key":"612_CR93","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","volume":"1173","author":"S Lacotte","year":"2009","unstructured":"Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci. 2009;1173:310\u20137. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04813.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"612_CR94","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41467-020-15404-8","volume":"11","author":"AJ Gunderson","year":"2020","unstructured":"Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A, et al. TGFbeta suppresses CD8(+) T cell expression of CXCR3 and tumor trafficking. Nat Commun. 2020;11(1):1749. https:\/\/doi.org\/10.1038\/s41467-020-15404-8.","journal-title":"Nat Commun"},{"issue":"1","key":"612_CR95","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska N, Cardenas MA, Valanparambil RM, Sobierajska E, Barwick BG, Jansen C, et al. CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. 2023;56(1):107-24 e5. https:\/\/doi.org\/10.1016\/j.immuni.2022.12.002.","journal-title":"Immunity"},{"key":"612_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102510","volume":"92","author":"TR Mempel","year":"2025","unstructured":"Mempel TR, Malehmir M. Chemokines that govern T cell activity in tumors. Curr Opin Immunol. 2025;92:102510. https:\/\/doi.org\/10.1016\/j.coi.2024.102510.","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"612_CR97","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1172\/JCI44952","volume":"121","author":"DT Fisher","year":"2011","unstructured":"Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011;121(10):3846\u201359. https:\/\/doi.org\/10.1172\/JCI44952.","journal-title":"J Clin Invest"},{"issue":"6","key":"612_CR98","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ijc.10074","volume":"97","author":"E Ryschich","year":"2002","unstructured":"Ryschich E, Schmidt J, Hammerling GJ, Klar E, Ganss R. Transformation of the microvascular system during multistage tumorigenesis. Int J Cancer. 2002;97(6):719\u201325. https:\/\/doi.org\/10.1002\/ijc.10074.","journal-title":"Int J Cancer"},{"issue":"15","key":"612_CR99","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1111\/febs.14992","volume":"286","author":"NK Karamanos","year":"2019","unstructured":"Karamanos NK. Extracellular matrix: key structural and functional meshwork in health and disease. FEBS J. 2019;286(15):2826\u20139. https:\/\/doi.org\/10.1111\/febs.14992.","journal-title":"FEBS J"},{"key":"612_CR100","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1146\/annurev.biochem.77.032207.120833","volume":"78","author":"MD Shoulders","year":"2009","unstructured":"Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929\u201358. https:\/\/doi.org\/10.1146\/annurev.biochem.77.032207.120833.","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"612_CR101","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1007\/s13277-013-1511-7","volume":"35","author":"M Fang","year":"2014","unstructured":"Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. Tumour Biol. 2014;35(4):2871\u201382. https:\/\/doi.org\/10.1007\/s13277-013-1511-7.","journal-title":"Tumour Biol"},{"issue":"5","key":"612_CR102","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891\u2013906. https:\/\/doi.org\/10.1016\/j.cell.2009.10.027.","journal-title":"Cell"},{"issue":"1","key":"612_CR103","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2741\/3613","volume":"15","author":"F Xing","year":"2010","unstructured":"Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed). 2010;15(1):166\u201379. https:\/\/doi.org\/10.2741\/3613.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"612_CR104","doi-asserted-by":"publisher","unstructured":"Wright K, Ly T, Kriet M, Czirok A, Thomas SM. Cancer-Associated Fibroblasts: Master Tumor Microenvironment Modifiers. Cancers (Basel). 2023;15(6). https:\/\/doi.org\/10.3390\/cancers15061899","DOI":"10.3390\/cancers15061899"},{"issue":"16","key":"612_CR105","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins L, Jungwirth U, Avgustinova A, Iravani M, Mills A, Haider S, et al. Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade. Cancer Res. 2022;82(16):2904\u201317. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4141.","journal-title":"Cancer Res"},{"key":"612_CR106","doi-asserted-by":"publisher","unstructured":"Murdamoothoo D, Sun Z, Yilmaz A, Riegel G, Abou-Faycal C, Deligne C, et al. Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression. EMBO Mol Med. 2021;13(6):e13270. https:\/\/doi.org\/10.15252\/emmm.202013270","DOI":"10.15252\/emmm.202013270"},{"issue":"1","key":"612_CR107","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1038\/s41467-023-43548-w","volume":"14","author":"S Shang","year":"2023","unstructured":"Shang S, Yang C, Chen F, Xiang RS, Zhang H, Dai SY, et al. ID1 expressing macrophages support cancer cell stemness and limit CD8(+) T cell infiltration in colorectal cancer. Nat Commun. 2023;14(1):7661. https:\/\/doi.org\/10.1038\/s41467-023-43548-w.","journal-title":"Nat Commun"},{"issue":"6","key":"612_CR108","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/cac2.12311","volume":"42","author":"W Zhang","year":"2022","unstructured":"Zhang W, Zhang Q, Yang N, Shi Q, Su H, Lin T, et al. Crosstalk between IL-15Ralpha(+) tumor-associated macrophages and breast cancer cells reduces CD8(+) T cell recruitment. Cancer Commun (Lond). 2022;42(6):536\u201357. https:\/\/doi.org\/10.1002\/cac2.12311.","journal-title":"Cancer Commun (Lond)"},{"key":"612_CR109","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fonc.2012.00058","volume":"2","author":"G Multhoff","year":"2012","unstructured":"Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2012;2:58. https:\/\/doi.org\/10.3389\/fonc.2012.00058.","journal-title":"Front Oncol"},{"key":"612_CR110","doi-asserted-by":"publisher","unstructured":"Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J Immunother Cancer. 2020;8(1). https:\/\/doi.org\/10.1136\/jitc-2020-000610.","DOI":"10.1136\/jitc-2020-000610"},{"key":"612_CR111","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fimmu.2016.00222","volume":"7","author":"VL Wehbi","year":"2016","unstructured":"Wehbi VL, Tasken K. Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units. Front Immunol. 2016;7:222. https:\/\/doi.org\/10.3389\/fimmu.2016.00222.","journal-title":"Front Immunol"},{"key":"612_CR112","doi-asserted-by":"publisher","unstructured":"Chimote AA, Hajdu P, Kucher V, Boiko N, Kuras Z, Szilagyi O, et al. Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells. J Immunol. 2013;191(12):6273\u201380. https:\/\/doi.org\/10.4049\/jimmunol.1300702","DOI":"10.4049\/jimmunol.1300702"},{"issue":"3","key":"612_CR113","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clim.2006.01.016","volume":"119","author":"JY Park","year":"2006","unstructured":"Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol. 2006;119(3):229\u201340. https:\/\/doi.org\/10.1016\/j.clim.2006.01.016.","journal-title":"Clin Immunol"},{"key":"612_CR114","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3389\/fimmu.2018.01859","volume":"9","author":"A Park","year":"2018","unstructured":"Park A, Lee Y, Kim MS, Kang YJ, Park YJ, Jung H, et al. Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation. Front Immunol. 2018;9:1859. https:\/\/doi.org\/10.3389\/fimmu.2018.01859.","journal-title":"Front Immunol"},{"issue":"5","key":"612_CR115","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1158\/1535-7163.MCT-20-0699","volume":"20","author":"MS Gilardini Montani","year":"2021","unstructured":"Gilardini Montani MS, Benedetti R, Piconese S, Pulcinelli FM, Timperio AM, Romeo MA, et al. PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCs Impairing Their Immune Function. Mol Cancer Ther. 2021;20(5):934\u201345. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0699.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"612_CR116","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ajpath.2017.10.025","volume":"188","author":"K Esbona","year":"2018","unstructured":"Esbona K, Yi Y, Saha S, Yu M, Van Doorn RR, Conklin MW, et al. The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. Am J Pathol. 2018;188(3):559\u201373. https:\/\/doi.org\/10.1016\/j.ajpath.2017.10.025.","journal-title":"Am J Pathol"},{"issue":"3\u20134","key":"612_CR117","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.molimm.2013.03.019","volume":"55","author":"J Kim","year":"2013","unstructured":"Kim J, Lee S, Kim YM, Jeoung DI, Choe J. Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins. Mol Immunol. 2013;55(3\u20134):418\u201323. https:\/\/doi.org\/10.1016\/j.molimm.2013.03.019.","journal-title":"Mol Immunol"},{"issue":"3","key":"612_CR118","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12032-013-0663-z","volume":"30","author":"T Li","year":"2013","unstructured":"Li T, Yi S, Liu W, Jia C, Wang G, Hua X, et al. Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity. Med Oncol. 2013;30(3):663. https:\/\/doi.org\/10.1007\/s12032-013-0663-z.","journal-title":"Med Oncol"},{"issue":"4","key":"612_CR119","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.3390\/ijms14046542","volume":"14","author":"S De Keijzer","year":"2013","unstructured":"De Keijzer S, Meddens MB, Torensma R, Cambi A. The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle. Int J Mol Sci. 2013;14(4):6542\u201355. https:\/\/doi.org\/10.3390\/ijms14046542.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"612_CR120","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1476-5381.2011.01800.x","volume":"166","author":"KW Brudvik","year":"2012","unstructured":"Brudvik KW, Tasken K. Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states. Br J Pharmacol. 2012;166(2):411\u20139. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01800.x.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"612_CR121","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/bcr3115","volume":"14","author":"H Bronger","year":"2012","unstructured":"Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stockel A, Avril S, et al. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res. 2012;14(1):R30. https:\/\/doi.org\/10.1186\/bcr3115.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"612_CR122","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54\u201361. https:\/\/doi.org\/10.1038\/nm1523.","journal-title":"Nat Med"},{"issue":"10","key":"612_CR123","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170\u20138. https:\/\/doi.org\/10.1038\/nm.2028.","journal-title":"Nat Med."},{"issue":"9","key":"612_CR124","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050\u20139. https:\/\/doi.org\/10.1038\/nm1622.","journal-title":"Nat Med"},{"issue":"10","key":"612_CR125","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.4049\/jimmunol.1003477","volume":"187","author":"G Garrido","year":"2011","unstructured":"Garrido G, Rabasa A, Sanchez B, Lopez MV, Blanco R, Lopez A, et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol. 2011;187(10):4954\u201366. https:\/\/doi.org\/10.4049\/jimmunol.1003477.","journal-title":"J Immunol"},{"issue":"11","key":"612_CR126","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301\u20139. https:\/\/doi.org\/10.1038\/nm.3708.","journal-title":"Nat Med"},{"issue":"2","key":"612_CR127","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccell.2021.12.009","volume":"40","author":"E Limagne","year":"2022","unstructured":"Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell. 2022;40(2):136-52 e12. https:\/\/doi.org\/10.1016\/j.ccell.2021.12.009.","journal-title":"Cancer Cell"},{"issue":"1","key":"612_CR128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1590\/1413-81232022271.20002021","volume":"27","author":"JM Schenkel","year":"2022","unstructured":"Schenkel JM, Silva G, Amorin A, Miranda FAN, Carvalho JBL, Ribeiro SEA, et al. Mental health, art, and deinstitutionalization: an aesthetic-poetic-theatrical account of the city\u2019s occupation. Cien Saude Colet. 2022;27(1):39\u201348. https:\/\/doi.org\/10.1590\/1413-81232022271.20002021.","journal-title":"Cien Saude Colet"},{"issue":"7265","key":"612_CR129","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461(7265):788\u201392. https:\/\/doi.org\/10.1038\/nature08476.","journal-title":"Nature"},{"issue":"1","key":"612_CR130","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov. 2020;10(1):26\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0761.","journal-title":"Cancer Discov"},{"issue":"50","key":"612_CR131","doi-asserted-by":"publisher","first-page":"15408","DOI":"10.1073\/pnas.1512832112","volume":"112","author":"O Demaria","year":"2015","unstructured":"Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci U S A. 2015;112(50):15408\u201313. https:\/\/doi.org\/10.1073\/pnas.1512832112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"612_CR132","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014;41(5):843\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019.","journal-title":"Immunity"},{"key":"612_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101057","volume":"26","author":"T Chellen","year":"2024","unstructured":"Chellen T, Bausart M, Maus P, Vanvarenberg K, Limaye N, Preat V, et al. In situ administration of STING-activating hyaluronic acid conjugate primes anti-glioblastoma immune response. Mater Today Bio. 2024;26:101057. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101057.","journal-title":"Mater Today Bio"},{"key":"612_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.969678","volume":"13","author":"PT Graham","year":"2022","unstructured":"Graham PT, Nowak AK, Cornwall SMJ, Larma I, Nelson DJ. The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model. Front Immunol. 2022;13:969678. https:\/\/doi.org\/10.3389\/fimmu.2022.969678.","journal-title":"Front Immunol"},{"issue":"12","key":"612_CR135","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/sj.bjc.6604808","volume":"99","author":"MJ McKeage","year":"2008","unstructured":"McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 2008;99(12):2006\u201312. https:\/\/doi.org\/10.1038\/sj.bjc.6604808.","journal-title":"Br J Cancer"},{"issue":"16","key":"612_CR136","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, et al. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8(+) T-cell Infiltration. Clin Cancer Res. 2017;23(16):4556\u201368. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2821.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"612_CR137","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood-2009-12-256065","volume":"116","author":"RH Mounzer","year":"2010","unstructured":"Mounzer RH, Svendsen OS, Baluk P, Bergman CM, Padera TP, Wiig H, et al. Lymphotoxin-alpha contributes to lymphangiogenesis. Blood. 2010;116(12):2173\u201382. https:\/\/doi.org\/10.1182\/blood-2009-12-256065.","journal-title":"Blood"},{"issue":"11","key":"612_CR138","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/ni.3836","volume":"18","author":"A Johansson-Percival","year":"2017","unstructured":"Johansson-Percival A, He B, Li ZJ, Kjellen A, Russell K, Li J, et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol. 2017;18(11):1207\u201317. https:\/\/doi.org\/10.1038\/ni.3836.","journal-title":"Nat Immunol"},{"issue":"1","key":"612_CR139","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","volume":"169","author":"SA Luther","year":"2002","unstructured":"Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 2002;169(1):424\u201333. https:\/\/doi.org\/10.4049\/jimmunol.169.1.424.","journal-title":"J Immunol"},{"issue":"1\u20132","key":"612_CR140","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11010-014-2285-y","volume":"400","author":"Z Zhu","year":"2015","unstructured":"Zhu Z, Zhang X, Guo H, Fu L, Pan G, Sun Y. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K\/AKT pathway. Mol Cell Biochem. 2015;400(1\u20132):287\u201395. https:\/\/doi.org\/10.1007\/s11010-014-2285-y.","journal-title":"Mol Cell Biochem"},{"key":"612_CR141","doi-asserted-by":"publisher","first-page":"1305664","DOI":"10.1155\/2024\/1305664","volume":"2024","author":"M Ukita","year":"2024","unstructured":"Ukita M, Matsuyama R, Isoda N, Omori R, Yamamoto T, Makita K. Identifying Effective Biosecurity Measures for Preventing the Introduction of Classical Swine Fever in Pig Farms in Japan: Under the Condition of Absence\/Presence of Observable Infected Wild Boar. Transbound Emerg Dis. 2024;2024:1305664. https:\/\/doi.org\/10.1155\/2024\/1305664.","journal-title":"Transbound Emerg Dis"},{"issue":"1","key":"612_CR142","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1078-0432.CCR-24-1594","volume":"31","author":"T Lanickova","year":"2025","unstructured":"Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, et al. Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer. Clin Cancer Res. 2025;31(1):164\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1594.","journal-title":"Clin Cancer Res"},{"key":"612_CR143","doi-asserted-by":"publisher","first-page":"1334408","DOI":"10.3389\/fimmu.2023.1334408","volume":"14","author":"D Wang","year":"2023","unstructured":"Wang D, Huang L, Qian D, Cao Y, Wu X, Xu P, et al. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma. Front Immunol. 2023;14:1334408. https:\/\/doi.org\/10.3389\/fimmu.2023.1334408.","journal-title":"Front Immunol"},{"issue":"1","key":"612_CR144","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12951-025-03301-5","volume":"23","author":"M Li","year":"2025","unstructured":"Li M, Lu L, Bao Q, Zhou M, Nie B, Liu Y, et al. Radiotherapy-derived engineered stem cell exosomes improve anti-glioma immunotherapy by promoting the formation of tertiary lymphoid structure and improve the release of type I interferon. J Nanobiotechnology. 2025;23(1):239. https:\/\/doi.org\/10.1186\/s12951-025-03301-5.","journal-title":"J Nanobiotechnology"},{"issue":"7791","key":"612_CR145","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature"},{"issue":"7","key":"612_CR146","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41416-024-02598-7","volume":"130","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhang R, Jin D, Zhang T, Shahatiaili A, Zang J, et al. Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer. Br J Cancer. 2024;130(7):1221\u201331. https:\/\/doi.org\/10.1038\/s41416-024-02598-7.","journal-title":"Br J Cancer"},{"issue":"11","key":"612_CR147","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/s41590-024-01990-y","volume":"25","author":"X Liu","year":"2024","unstructured":"Liu X, Duda DG. Involuted TLS as a harbinger of HCC regression. Nat Immunol. 2024;25(11):1986\u20137. https:\/\/doi.org\/10.1038\/s41590-024-01990-y.","journal-title":"Nat Immunol"},{"issue":"11","key":"612_CR148","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","volume":"25","author":"DH Shu","year":"2024","unstructured":"Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, et al. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma. Nat Immunol. 2024;25(11):2110\u201323. https:\/\/doi.org\/10.1038\/s41590-024-01992-w.","journal-title":"Nat Immunol"},{"issue":"1","key":"612_CR149","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1038\/s41467-025-65421-8","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang G, Zhang X, Liu G, Zhang L, Chen L, et al. Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer. Nat Commun. 2025;16(1):10435. https:\/\/doi.org\/10.1038\/s41467-025-65421-8.","journal-title":"Nat Commun"},{"issue":"3","key":"612_CR150","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","volume":"29","author":"T Cascone","year":"2023","unstructured":"Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023;29(3):593\u2013604. https:\/\/doi.org\/10.1038\/s41591-022-02189-0.","journal-title":"Nat Med"},{"issue":"11","key":"612_CR151","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649\u201354. https:\/\/doi.org\/10.1038\/s41591-018-0197-1.","journal-title":"Nat Med"},{"issue":"7","key":"612_CR152","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","volume":"2","author":"ER Lutz","year":"2014","unstructured":"Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2(7):616\u201331. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0027.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"612_CR153","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13740","volume":"58","author":"MJ Zhang","year":"2025","unstructured":"Zhang MJ, Lin WP, Wang Q, Wang S, Song A, Wang YY, et al. Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10\/CXCR3 to boost antitumor immunity. Cell Prolif. 2025;58(1):e13740. https:\/\/doi.org\/10.1111\/cpr.13740.","journal-title":"Cell Prolif"},{"issue":"1","key":"612_CR154","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-024-03324-9","volume":"31","author":"R Li","year":"2025","unstructured":"Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, et al. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025;31(1):176\u201388. https:\/\/doi.org\/10.1038\/s41591-024-03324-9.","journal-title":"Nat Med"},{"key":"612_CR155","doi-asserted-by":"publisher","unstructured":"Liu J, Chen H, Guo C, Li J, Li M, Zhao M, et al. Sulforaphane activates CD8(+) T cells antitumor response through IL-12RB2\/MMP3\/FasL-induced MDSCs apoptosis\u2019. J Immunother Cancer. 2024;12(1). https:\/\/doi.org\/10.1136\/jitc-2023-007983.","DOI":"10.1136\/jitc-2023-007983"},{"issue":"8","key":"612_CR156","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/cgt.2013.42","volume":"20","author":"L Chen","year":"2013","unstructured":"Chen L, Taylor JL, Sabins NC, Lowe DB, Qu Y, You Z, et al. Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther. 2013;20(8):469\u201377. https:\/\/doi.org\/10.1038\/cgt.2013.42.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"612_CR157","doi-asserted-by":"publisher","first-page":"7861","DOI":"10.1038\/s41598-018-26265-z","volume":"8","author":"SE Dorraji","year":"2018","unstructured":"Dorraji SE, Hovd AK, Kanapathippillai P, Bakland G, Eilertsen GO, Figenschau SL, et al. Mesenchymal stem cells and T cells in the formation of Tertiary Lymphoid Structures in Lupus Nephritis. Sci Rep. 2018;8(1):7861. https:\/\/doi.org\/10.1038\/s41598-018-26265-z.","journal-title":"Sci Rep"},{"key":"612_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216507","volume":"582","author":"G Chen","year":"2024","unstructured":"Chen G, Zheng D, Zhou Y, Du S, Zeng Z. Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma. Cancer Lett. 2024;582:216507. https:\/\/doi.org\/10.1016\/j.canlet.2023.216507.","journal-title":"Cancer Lett"},{"issue":"1","key":"612_CR159","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41467-025-57257-z","volume":"16","author":"X Ran","year":"2025","unstructured":"Ran X, Wu BX, Vidhyasagar V, Song L, Zhang X, Ladak RJ, et al. PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer. Nat Commun. 2025;16(1):2166. https:\/\/doi.org\/10.1038\/s41467-025-57257-z.","journal-title":"Nat Commun"},{"issue":"2","key":"612_CR160","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41590-021-01120-y","volume":"23","author":"M Bruchard","year":"2022","unstructured":"Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, et al. Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nat Immunol. 2022;23(2):262\u201374. https:\/\/doi.org\/10.1038\/s41590-021-01120-y.","journal-title":"Nat Immunol"},{"issue":"7","key":"612_CR161","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity. 2023;56(7):1613-30 e5. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.003.","journal-title":"Immunity"},{"issue":"26","key":"612_CR162","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1182\/blood.2020007197","volume":"136","author":"DC Dale","year":"2020","unstructured":"Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, Gorelick KJ, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994\u20133003. https:\/\/doi.org\/10.1182\/blood.2020007197.","journal-title":"Blood"},{"issue":"4","key":"612_CR163","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1097\/MS9.0000000000003030","volume":"87","author":"A Waheed","year":"2024","unstructured":"Waheed A, Gul MH, Ilmaguook B, Wardak AB, Sadeed F, Hussaini H, et al. Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024. Ann Med Surg. 2024;87(4):1777\u20139. https:\/\/doi.org\/10.1097\/MS9.0000000000003030.","journal-title":"Ann Med Surg"},{"key":"612_CR164","doi-asserted-by":"publisher","first-page":"1410942","DOI":"10.3389\/fphar.2024.1410942","volume":"15","author":"P Muthuramalingam","year":"2024","unstructured":"Muthuramalingam P, Jeyasri R, Varadharajan V, Priya A, Dhanapal AR, Shin H, et al. Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy-a review. Front Pharmacol. 2024;15:1410942. https:\/\/doi.org\/10.3389\/fphar.2024.1410942.","journal-title":"Front Pharmacol"},{"issue":"3","key":"612_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100543","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3(3):100543. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100543.","journal-title":"Cell Rep Med"},{"issue":"8","key":"612_CR166","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33(8):780\u20138. https:\/\/doi.org\/10.1097\/CJI.0b013e3181ee6675.","journal-title":"J Immunother"},{"issue":"14","key":"612_CR167","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0351.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"612_CR168","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712\u201324. https:\/\/doi.org\/10.1002\/eji.201948457.","journal-title":"Eur J Immunol"},{"issue":"1","key":"612_CR169","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10(1):4016. https:\/\/doi.org\/10.1038\/s41467-019-11869-4.","journal-title":"Nat Commun"},{"key":"612_CR170","doi-asserted-by":"publisher","unstructured":"Whilding LM, Halim L, Draper B, Parente-Pereira AC, Zabinski T, Davies DM, et al. CAR T-Cells Targeting the Integrin alphavbeta6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. Cancers (Basel). 2019;11(5). https:\/\/doi.org\/10.3390\/cancers11050674","DOI":"10.3390\/cancers11050674"},{"issue":"1","key":"612_CR171","doi-asserted-by":"publisher","first-page":"9914","DOI":"10.1038\/s41467-025-64861-6","volume":"16","author":"EZ Song","year":"2025","unstructured":"Song EZ, Timpanaro A, Meechan M, Elena-Sanchez L, Li LZ, Jamet S, et al. Engineered CXCR3-A expression enhances B7\u2013H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma. Nat Commun. 2025;16(1):9914. https:\/\/doi.org\/10.1038\/s41467-025-64861-6.","journal-title":"Nat Commun"},{"key":"612_CR172","doi-asserted-by":"publisher","unstructured":"Talbot LJ, Chabot A, Ross AB, Beckett A, Nguyen P, Fleming A, et al. Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Clin Cancer Res. 2024;30(19):4434\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3298","DOI":"10.1158\/1078-0432.CCR-23-3298"},{"issue":"1","key":"612_CR173","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-025-02522-2","volume":"11","author":"P Shu","year":"2026","unstructured":"Shu P, Guo F, Qin D, Zou L, Ma Q, Zhang B, et al. CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies. Signal Transduct Target Ther. 2026;11(1):38. https:\/\/doi.org\/10.1038\/s41392-025-02522-2.","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"612_CR174","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392\u2013402. https:\/\/doi.org\/10.1182\/blood-2009-03-209650.","journal-title":"Blood"},{"issue":"5706","key":"612_CR175","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362. https:\/\/doi.org\/10.1126\/science.1104819.","journal-title":"Science"},{"issue":"3","key":"612_CR176","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071\u2013121. https:\/\/doi.org\/10.1152\/physrev.00038.2010.","journal-title":"Physiol Rev"},{"issue":"3","key":"612_CR177","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006486","volume":"2","author":"S Goel","year":"2012","unstructured":"Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486. https:\/\/doi.org\/10.1101\/cshperspect.a006486.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"612_CR178","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2004.10.011","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553\u201363. https:\/\/doi.org\/10.1016\/j.ccr.2004.10.011.","journal-title":"Cancer Cell"},{"issue":"43","key":"612_CR179","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561\u20136. https:\/\/doi.org\/10.1073\/pnas.1215397109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"612_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"612_CR181","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145\u20137. https:\/\/doi.org\/10.1038\/nm988.","journal-title":"Nat Med"},{"issue":"12","key":"612_CR182","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A de Gramont","year":"2012","unstructured":"de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(12)70509-0.","journal-title":"Lancet Oncol"},{"issue":"23","key":"612_CR183","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.1158\/0008-5472.CAN-13-2532","volume":"73","author":"M Arjaans","year":"2013","unstructured":"Arjaans M, Oosting SF, Schroder CP, de Vries EG. Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies\u2013response. Cancer Res. 2013;73(23):7147\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2532.","journal-title":"Cancer Res"},{"issue":"3","key":"612_CR184","first-page":"881","volume":"29","author":"J Wada","year":"2009","unstructured":"Wada J, Suzuki H, Fuchino R, Yamasaki A, Nagai S, Yanai K, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 2009;29(3):881\u20138.","journal-title":"Anticancer Res"},{"issue":"7","key":"612_CR185","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/sj.bjc.6604965","volume":"100","author":"C Alfaro","year":"2009","unstructured":"Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009;100(7):1111\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6604965.","journal-title":"Br J Cancer"},{"issue":"10","key":"612_CR186","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2326-6066.CIR-16-0084","volume":"4","author":"X Wu","year":"2016","unstructured":"Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, et al. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunol Res. 2016;4(10):858\u201368. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0084.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"612_CR187","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/eji.200939887","volume":"40","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol. 2010;40(1):197\u2013203. https:\/\/doi.org\/10.1002\/eji.200939887.","journal-title":"Eur J Immunol"},{"issue":"6","key":"612_CR188","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00262-006-0234-7","volume":"56","author":"K Mimura","year":"2007","unstructured":"Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother. 2007;56(6):761\u201370. https:\/\/doi.org\/10.1007\/s00262-006-0234-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"612_CR189","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","volume":"64","author":"RT Tong","year":"2004","unstructured":"Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0074.","journal-title":"Cancer Res"},{"issue":"1","key":"612_CR190","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1096\/fj.14-250985","volume":"29","author":"H Huang","year":"2015","unstructured":"Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. FASEB J. 2015;29(1):227\u201338. https:\/\/doi.org\/10.1096\/fj.14-250985.","journal-title":"FASEB J"},{"key":"612_CR191","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12967-014-0294-y","volume":"12","author":"AR Kwilas","year":"2014","unstructured":"Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12:294. https:\/\/doi.org\/10.1186\/s12967-014-0294-y.","journal-title":"J Transl Med"},{"key":"612_CR192","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516. https:\/\/doi.org\/10.1038\/ncomms3516.","journal-title":"Nat Commun"},{"issue":"7","key":"612_CR193","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","volume":"5","author":"JE Murphy","year":"2019","unstructured":"Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019;5(7):1020\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0892.","journal-title":"JAMA Oncol"},{"issue":"3","key":"612_CR194","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418\u201329. https:\/\/doi.org\/10.1016\/j.ccr.2012.01.007.","journal-title":"Cancer Cell"},{"issue":"1","key":"612_CR195","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112\u201320. https:\/\/doi.org\/10.1136\/gutjnl-2012-302529.","journal-title":"Gut"},{"issue":"8","key":"612_CR196","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1200\/JCO.2005.04.5302","volume":"24","author":"DA Reardon","year":"2006","unstructured":"Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006;24(8):1253\u201365. https:\/\/doi.org\/10.1200\/JCO.2005.04.5302.","journal-title":"J Clin Oncol"},{"issue":"6","key":"612_CR197","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719\u201334. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.005.","journal-title":"Cancer Cell"},{"issue":"14","key":"612_CR198","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1158\/1078-0432.CCR-07-5211","volume":"14","author":"E Ostermann","year":"2008","unstructured":"Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008;14(14):4584\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5211.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"612_CR199","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-02-2829","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9(5):1639\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-02-2829.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"612_CR200","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000069863","volume":"26","author":"RD Hofheinz","year":"2003","unstructured":"Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26(1):44\u20138. https:\/\/doi.org\/10.1159\/000069863.","journal-title":"Onkologie"},{"key":"612_CR201","doi-asserted-by":"publisher","unstructured":"Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology. 2011;141(4):1486\u201397, 97 e1\u201314. https:\/\/doi.org\/10.1053\/j.gastro.2011.06.047","DOI":"10.1053\/j.gastro.2011.06.047"},{"issue":"3","key":"612_CR202","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/path.4727","volume":"239","author":"EF Carapuca","year":"2016","unstructured":"Carapuca EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, et al. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. J Pathol. 2016;239(3):286\u201396. https:\/\/doi.org\/10.1002\/path.4727.","journal-title":"J Pathol"},{"issue":"50","key":"612_CR203","doi-asserted-by":"publisher","first-page":"82889","DOI":"10.18632\/oncotarget.12658","volume":"7","author":"K Takai","year":"2016","unstructured":"Takai K, Le A, Weaver VM, Werb Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 2016;7(50):82889\u2013901. https:\/\/doi.org\/10.18632\/oncotarget.12658.","journal-title":"Oncotarget"},{"issue":"7","key":"612_CR204","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-12-3180","volume":"73","author":"S Kozono","year":"2013","unstructured":"Kozono S, Ohuchida K, Eguchi D, Ikenaga N, Fujiwara K, Cui L, et al. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 2013;73(7):2345\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3180.","journal-title":"Cancer Res"},{"issue":"21","key":"612_CR205","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1200\/JCO.22.02760","volume":"41","author":"LB Saltz","year":"2023","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. J Clin Oncol. 2023;41(21):3663\u20139. https:\/\/doi.org\/10.1200\/JCO.22.02760.","journal-title":"J Clin Oncol"},{"issue":"1","key":"612_CR206","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41392-024-01788-2","volume":"9","author":"QZ Pan","year":"2024","unstructured":"Pan QZ, Zhao JJ, Liu L, Zhang DS, Wang LP, Hu WW, et al. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal Transduct Target Ther. 2024;9(1):79. https:\/\/doi.org\/10.1038\/s41392-024-01788-2.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"612_CR207","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909\u201324. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.009.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"612_CR208","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445\u201360. https:\/\/doi.org\/10.1038\/s41573-024-00920-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"612_CR209","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/jamaoncol.2023.5456","volume":"10","author":"TW Chen","year":"2024","unstructured":"Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC, et al. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2024;10(3):325\u201334. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5456.","journal-title":"JAMA Oncol"},{"issue":"1","key":"612_CR210","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10143-024-02667-8","volume":"47","author":"MA Habibi","year":"2024","unstructured":"Habibi MA, Shad N, Mirjnani MS, Fasihi S, Sadeghi S, Karami S, et al. Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis. Neurosurg Rev. 2024;47(1):445. https:\/\/doi.org\/10.1007\/s10143-024-02667-8.","journal-title":"Neurosurg Rev"},{"issue":"4","key":"612_CR211","doi-asserted-by":"publisher","first-page":"700","DOI":"10.4103\/neurol-india.Neurol-India-D-23-00346","volume":"72","author":"F Yang","year":"2024","unstructured":"Yang F, Wang L, Zhao W, Wang S, Li J, Sun A, et al. A Systematic Review and Meta-Analysis on the Effectiveness of Radiotherapy and Temozolomide Treatment With or Without Bevacizumab in Patients With Glioblastoma Multiforme. Neurol India. 2024;72(4):700\u20137. https:\/\/doi.org\/10.4103\/neurol-india.Neurol-India-D-23-00346.","journal-title":"Neurol India"},{"key":"612_CR212","doi-asserted-by":"publisher","first-page":"1662160","DOI":"10.3389\/fonc.2025.1662160","volume":"15","author":"H Liu","year":"2025","unstructured":"Liu H, Chang X, Hong Y, Yin H, Zhang H, Wufuer G, et al. Efficacy and safety of anlotinib hydrochloride combined with concurrent radiotherapy in the treatment of locally advanced cervical cancer: a single-arm, single-center, exploratory, phase II clinical study. Front Oncol. 2025;15:1662160. https:\/\/doi.org\/10.3389\/fonc.2025.1662160.","journal-title":"Front Oncol"},{"issue":"6","key":"612_CR213","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","volume":"21","author":"HY Kuo","year":"2024","unstructured":"Kuo HY, Khan KA, Kerbel RS. Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nat Rev Clin Oncol. 2024;21(6):468\u201382. https:\/\/doi.org\/10.1038\/s41571-024-00886-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"612_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156842","volume":"186","author":"K Matsuda","year":"2025","unstructured":"Matsuda K, Ota Y, Uemachi H, Taoda R, Tsunashima Y, Ban H, et al. Examination of the potential clinical application of 5DEX-0509R, the tumor macrophage-targeting nanomedicine. Cytokine. 2025;186:156842. https:\/\/doi.org\/10.1016\/j.cyto.2024.156842.","journal-title":"Cytokine"},{"issue":"1","key":"612_CR215","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12935-022-02708-6","volume":"22","author":"LA Zuniga","year":"2022","unstructured":"Zuniga LA, Lessmann T, Uppal K, Bisek N, Hong E, Rasmussen CE, et al. Intratumoral delivery of TransCon() TLR7\/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction. Cancer Cell Int. 2022;22(1):286. https:\/\/doi.org\/10.1186\/s12935-022-02708-6.","journal-title":"Cancer Cell Int"},{"issue":"18","key":"612_CR216","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-22-0339","volume":"28","author":"D Davar","year":"2022","unstructured":"Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, et al. Phase IB study of GITR agonist antibody TRX518 singly and in combination with gemcitabine, pembrolizumab, or nivolumab in patients with advanced solid tumors. Clin Cancer Res. 2022;28(18):3990\u20134002. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0339.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"612_CR217","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1172\/JCI125413","volume":"129","author":"H Yang","year":"2019","unstructured":"Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest. 2019;129(10):4350\u201364. https:\/\/doi.org\/10.1172\/JCI125413.","journal-title":"J Clin Invest"},{"issue":"2","key":"612_CR218","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13736","volume":"17","author":"D Robbrecht","year":"2024","unstructured":"Robbrecht D, Grob JJ, Bechter O, Simonelli M, Doger B, Borbath I, et al. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFbeta) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors. Clin Transl Sci. 2024;17(2):e13736. https:\/\/doi.org\/10.1111\/cts.13736.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"612_CR219","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41591-025-04157-w","volume":"32","author":"TA Yap","year":"2026","unstructured":"Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, et al. Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026;32(3):992\u20131001. https:\/\/doi.org\/10.1038\/s41591-025-04157-w.","journal-title":"Nat Med"},{"key":"612_CR220","doi-asserted-by":"publisher","unstructured":"Reid TR, Oronsky B, Williams J, Caroen S, Conley A. TGF-beta trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance. J Immunother Cancer. 2024;12(10). https:\/\/doi.org\/10.1136\/jitc-2024-009613","DOI":"10.1136\/jitc-2024-009613"},{"issue":"1","key":"612_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100748","volume":"6","author":"C Rolfo","year":"2025","unstructured":"Rolfo C, Greillier L, Veillon R, Badin F, Ghiringhelli F, Isambert N, et al. Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-beta and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC. JTO Clin Res Rep. 2025;6(1):100748. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100748.","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"612_CR222","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00262-024-03777-4","volume":"73","author":"NH Kim","year":"2024","unstructured":"Kim NH, Lee J, Kim SH, Kang SH, Bae S, Yu CH, et al. ALK5\/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects. Cancer Immunol Immunother. 2024;73(10):190. https:\/\/doi.org\/10.1007\/s00262-024-03777-4.","journal-title":"Cancer Immunol Immunother"},{"key":"612_CR223","doi-asserted-by":"publisher","unstructured":"Suarez-Carmona M, Williams A, Schreiber J, Hohmann N, Pruefer U, Krauss J, et al. Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. J Immunother Cancer. 2021;9(10). https:\/\/doi.org\/10.1136\/jitc-2021-002505.","DOI":"10.1136\/jitc-2021-002505"},{"key":"612_CR224","doi-asserted-by":"publisher","unstructured":"Makranz C, Huguely C, Zhang M, Davis D, Anderson B, Haynes T, et al. Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific manner. Neurooncol Adv. 2026;8(1):vdag118. https:\/\/doi.org\/10.1093\/noajnl\/vdag118","DOI":"10.1093\/noajnl\/vdag118"},{"issue":"1","key":"612_CR225","doi-asserted-by":"publisher","first-page":"2543614","DOI":"10.1080\/2162402X.2025.2543614","volume":"14","author":"KM Bever","year":"2025","unstructured":"Bever KM, Shin SM, Durham JN, Qi H, Hernandez A, Coyne EM, et al. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages. Oncoimmunology. 2025;14(1):2543614. https:\/\/doi.org\/10.1080\/2162402X.2025.2543614.","journal-title":"Oncoimmunology"},{"issue":"19","key":"612_CR226","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1158\/1078-0432.CCR-18-1025","volume":"24","author":"EQ Lee","year":"2018","unstructured":"Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, et al. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018;24(19):4643\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1025.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"612_CR227","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","volume":"15","author":"FA Giordano","year":"2024","unstructured":"Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D, et al. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I\/II GLORIA trial. Nat Commun. 2024;15(1):4210. https:\/\/doi.org\/10.1038\/s41467-024-48416-9.","journal-title":"Nat Commun"},{"key":"612_CR228","doi-asserted-by":"publisher","unstructured":"Giordano FA, Layer JP, Turiello R, Friker LL, Mirallas O, Pregler BEF, et al. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I\/II GLORIA trial. Nat Commun. 2026;17(1). https:\/\/doi.org\/10.1038\/s41467-026-71362-7","DOI":"10.1038\/s41467-026-71362-7"},{"issue":"6","key":"612_CR229","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878\u201385. https:\/\/doi.org\/10.1038\/s41591-020-0880-x.","journal-title":"Nat Med"},{"issue":"23","key":"612_CR230","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1158\/0008-5472.CAN-23-2716","volume":"84","author":"D An","year":"2024","unstructured":"An D, Chen G, Cheng WY, Mohrs K, Adler C, Gupta NT, et al. LTbetaR Agonism Promotes Antitumor Immune Responses via Modulation of the Tumor Microenvironment. Cancer Res. 2024;84(23):3984\u20134001. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2716.","journal-title":"Cancer Res"},{"issue":"12","key":"612_CR231","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.1021\/acsnano.4c01180","volume":"18","author":"G Kuang","year":"2024","unstructured":"Kuang G, Zhang Q, Li W, Zhao Y. Biomimetic tertiary lymphoid structures with microporous annealed particle scaffolds for cancer postoperative therapy. ACS Nano. 2024;18(12):9176\u201386. https:\/\/doi.org\/10.1021\/acsnano.4c01180.","journal-title":"ACS Nano"},{"key":"612_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123166","volume":"318","author":"W Ahn","year":"2025","unstructured":"Ahn W, Han J, Kim N, Hwang YH, Kim W, Lee Y, et al. Hierarchical protein nano-crystalline hydrogel with extracellular vesicles for ectopic lymphoid structure formation. Biomaterials. 2025;318:123166. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123166.","journal-title":"Biomaterials"},{"issue":"1","key":"612_CR233","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41467-024-55430-4","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhang B, Zhang MJ, Li W, Li H, Jiao Y, et al. Trigger inducible tertiary lymphoid structure formation using covalent organic frameworks for cancer immunotherapy. Nat Commun. 2025;16(1):44. https:\/\/doi.org\/10.1038\/s41467-024-55430-4.","journal-title":"Nat Commun"},{"key":"612_CR234","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bioactmat.2025.01.018","volume":"47","author":"QC Yang","year":"2025","unstructured":"Yang QC, Wang YY, Wang S, Song A, Wang WD, Zhang L, et al. Engineered bacterial membrane biomimetic covalent organic framework as nano-immunopotentiator for cancer immunotherapy. Bioact Mater. 2025;47:283\u201394. https:\/\/doi.org\/10.1016\/j.bioactmat.2025.01.018.","journal-title":"Bioact Mater"},{"issue":"10","key":"612_CR235","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1039\/d3mh00748k","volume":"10","author":"XK Jin","year":"2023","unstructured":"Jin XK, Liang JL, Zhang SM, Ji P, Huang QX, Qin YT, et al. Engineering metal-based hydrogel-mediated tertiary lymphoid structure formation via activation of the STING pathway for enhanced immunotherapy. Mater Horiz. 2023;10(10):4365\u201379. https:\/\/doi.org\/10.1039\/d3mh00748k.","journal-title":"Mater Horiz"},{"issue":"1","key":"612_CR236","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/neuonc\/noae167","volume":"27","author":"S Shen","year":"2025","unstructured":"Shen S, Cui Y, Li M, Yu K, Zhu Q, Zhang X, et al. Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity. Neuro Oncol. 2025;27(1):140\u201354. https:\/\/doi.org\/10.1093\/neuonc\/noae167.","journal-title":"Neuro Oncol"},{"issue":"6","key":"612_CR237","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","volume":"29","author":"J Lv","year":"2023","unstructured":"Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023;29(6):1424\u201336. https:\/\/doi.org\/10.1038\/s41591-023-02369-6.","journal-title":"Nat Med"},{"issue":"9","key":"612_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102298","volume":"6","author":"R Xing","year":"2025","unstructured":"Xing R, Mei J, Zuo Z, Zou H, Yu X, Xu J, et al. Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. Cell Rep Med. 2025;6(9):102298. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102298.","journal-title":"Cell Rep Med"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00612-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00612-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00612-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:05:11Z","timestamp":1791673511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00612-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":238,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00612-3","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"201"}}